Skip to main content
. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173

Table 2.

Patient baseline characteristics by model response type

Response type All patients, n Sensitive baseline mutation,* n (%) Insensitive baseline mutation,n (%) Imatinib-resistant, n (%) Imatinib-intolerant, n (%)
Slow (monophasic)
65
21 (32.3)
18 (27.7)
58 (89.2)
7 (10.8)
Fast (biphasic) 58 18 (31.0) 2 (3.4) 42 (72.4) 16 (27.6)

* Half maximal inhibitory concentration (IC50) ≤ 150 nm.

IC50 > 150 nm; Y253H, E255V/K, F359V/C.